JP2011526626A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526626A5
JP2011526626A5 JP2011516323A JP2011516323A JP2011526626A5 JP 2011526626 A5 JP2011526626 A5 JP 2011526626A5 JP 2011516323 A JP2011516323 A JP 2011516323A JP 2011516323 A JP2011516323 A JP 2011516323A JP 2011526626 A5 JP2011526626 A5 JP 2011526626A5
Authority
JP
Japan
Prior art keywords
composition
patient
polypeptide
actriia
activin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011516323A
Other languages
English (en)
Japanese (ja)
Other versions
JP5773868B2 (ja
JP2011526626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003838 external-priority patent/WO2009158033A2/en
Publication of JP2011526626A publication Critical patent/JP2011526626A/ja
Publication of JP2011526626A5 publication Critical patent/JP2011526626A5/ja
Application granted granted Critical
Publication of JP5773868B2 publication Critical patent/JP5773868B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011516323A 2008-06-26 2009-06-26 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用 Active JP5773868B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13336808P 2008-06-26 2008-06-26
US61/133,368 2008-06-26
PCT/US2009/003838 WO2009158033A2 (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014022289A Division JP2014088438A (ja) 2008-06-26 2014-02-07 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用

Publications (3)

Publication Number Publication Date
JP2011526626A JP2011526626A (ja) 2011-10-13
JP2011526626A5 true JP2011526626A5 (enExample) 2012-08-09
JP5773868B2 JP5773868B2 (ja) 2015-09-02

Family

ID=41445146

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2011516323A Active JP5773868B2 (ja) 2008-06-26 2009-06-26 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2014022289A Withdrawn JP2014088438A (ja) 2008-06-26 2014-02-07 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2015145499A Withdrawn JP2015187180A (ja) 2008-06-26 2015-07-23 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2016220297A Withdrawn JP2017036331A (ja) 2008-06-26 2016-11-11 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2018164195A Active JP6643432B2 (ja) 2008-06-26 2018-09-03 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2018164196A Withdrawn JP2018184484A (ja) 2008-06-26 2018-09-03 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2019231523A Withdrawn JP2020041002A (ja) 2008-06-26 2019-12-23 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2021176418A Withdrawn JP2022023184A (ja) 2008-06-26 2021-10-28 アクチビン－ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2014022289A Withdrawn JP2014088438A (ja) 2008-06-26 2014-02-07 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2015145499A Withdrawn JP2015187180A (ja) 2008-06-26 2015-07-23 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2016220297A Withdrawn JP2017036331A (ja) 2008-06-26 2016-11-11 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2018164195A Active JP6643432B2 (ja) 2008-06-26 2018-09-03 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2018164196A Withdrawn JP2018184484A (ja) 2008-06-26 2018-09-03 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2019231523A Withdrawn JP2020041002A (ja) 2008-06-26 2019-12-23 アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2021176418A Withdrawn JP2022023184A (ja) 2008-06-26 2021-10-28 アクチビン－ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用

Country Status (10)

Country Link
EP (4) EP2303917B1 (enExample)
JP (8) JP5773868B2 (enExample)
KR (4) KR20110031951A (enExample)
CN (2) CN102131515B (enExample)
AU (4) AU2009262968A1 (enExample)
CA (3) CA2729098C (enExample)
DK (1) DK2318028T3 (enExample)
ES (2) ES2852699T3 (enExample)
NZ (2) NZ590326A (enExample)
WO (2) WO2009158015A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR102170682B1 (ko) * 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
AU2015203400A1 (en) * 2009-08-13 2015-07-16 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2817008A1 (en) * 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
RU2678117C2 (ru) * 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CA2898121A1 (en) * 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
EP3131931B1 (en) * 2014-04-18 2020-10-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
JP6568110B2 (ja) * 2014-06-04 2019-08-28 アクセルロン ファーマ， インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CN113683708A (zh) * 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CA3043184A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
IL278546B2 (en) * 2018-05-09 2026-03-01 Keros Therapeutics Inc Activin receptor type IIA variants and methods of using them
JP7462907B2 (ja) 2018-11-15 2024-04-08 三菱ケミカル株式会社 改変型アクチビンａ
AU2020334924A1 (en) * 2019-08-22 2022-04-07 The Regents Of The University Of California UBE3A for the treatment of Angelman syndrome
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
CN119529092A (zh) * 2021-09-03 2025-02-28 来凯医药科技(上海)有限公司 抗acvr2a抗体及其用途
CN122404564A (zh) * 2025-01-15 2026-07-17 沈阳三生制药有限责任公司 一种ActRⅡB融合蛋白及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
EP0548276A4 (en) * 1990-09-13 1993-12-29 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
AU8921698A (en) 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
WO2002094864A2 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
WO2005025601A1 (en) 2003-09-15 2005-03-24 Monash University Follistatin isoforms and uses thereof
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
MX2007000976A (es) * 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
CA2587424A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
BRPI0618947B1 (pt) * 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
AU2007249827A1 (en) * 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
UA96452C2 (uk) * 2006-07-13 2011-11-10 Басф Се Зв'язувальний засіб, термопластична маса, що містить зв'язувальний засіб, формований виріб на основі термопластичної маси та спосіб одержання термопластичної маси та формованих виробів
MX2009000722A (es) * 2006-07-21 2009-06-11 Lyne Lab Composiciones liquidas de acetato de calcio.
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2672758C (en) * 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
DE102008016742B4 (de) * 2008-03-31 2010-01-14 Thyssenkrupp Presta Ag Lenksäule für ein Kraftfahrzeug

Similar Documents

Publication Publication Date Title
Mercurio et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model
US10577406B2 (en) FKBP-L polypeptides and uses in angiogenesis-mediated disorders
Yang et al. Pathogenesis and treatment of multiple myeloma
JP2026048860A (ja) 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ
JP5645408B2 (ja) 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
JP2008502738A (ja) ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
Li et al. Advances in bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma
Zhou et al. Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization
JP2010518006A5 (enExample)
JP2013504589A5 (enExample)
JP7373998B2 (ja) 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
CA3109702A1 (en) Peptides and compositions for targeted treatment and imaging
JP2021180671A (ja) Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
Wang et al. Autologous platelet delivery of siRNAs by autologous plasma protein self-assembled nanoparticles for the treatment of acute kidney injury
JP2014504591A (ja) ポリリンゴ酸ベースのナノバイオポリマー組成物およびがんを治療するための方法
CN105939724A (zh) 用于治疗和预防转移癌的药物组合物和方法
US20240293561A1 (en) Brain permeable multifunctional system and uses thereof
US20220323391A1 (en) Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
EP2752429B1 (en) Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof
US20200323960A1 (en) Pharmaceutical compositions comprising oncostatin m (osm) antagonist derivatives and methods of use
TW202206095A (zh) 使用精胺酸消除劑治療ａｍｌ亞型的方法
EP4225803B1 (en) Nanoparticle for anti-cancer peptides and uses thereof
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
CN119909193A (zh) 一种双特异性纳米抗体-核酸适体偶联物、衍生物、及其制备方法与应用
CN117940451A (zh) Epo变体和调节剂